International Phase 2 study investigates efficacy, safety and tolerability of AC102 in patients with sudden hearing loss at up to 45 European centers This is another important milestone on the way to a causal treatment of spontaneous hearing loss, which has a high...
At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022. AC102 is AudioCure’s clinical Phase I tested lead candidate for...
Phase I study confirms safety and tolerability of AC102 in patients with sudden hearing loss This is another important milestone that clears the way for a Phase 2 study evaluating AC102 in patients with sudden hearing loss Berlin, 7 September 2021 – AudioCure...
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...
This website uses cookies. By clicking on the “Ok” button, you consent to our use of cookies as described in our Privacy Notice. If you continue to use this site we will assume that you agree with our Privacy Police.OkRead more
